Bivalirudin found to be safer and more effective than heparin for treating Heart attack Patients

The most common anticoagulant used during primary percutaneous coronary intervention is heparin. However, its effects can be somewhat unpredictable, leading to higher-than-desirable rates of bleeding and blood clots. Bivalirudin is a newer anticoagulant that has more predictable “blood thinning” effects.
Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the most serious type of heart attacks who undergo urgent percutaneous coronary intervention (PCI), and can lower the risk of death or major bleeding by 31 percent finds a study, study was a Late Breaking Clinical Trial presentation at the American Heart Association’s Scientific Sessions (AHA 22) in Chicago, and published in The Lancet.

Get the latest medical and health news at medicaldialogues.in
Follow us on
Twitter:   / medicaldialogs  
Facebook:   / medicaldialogues  
Instagram:   / medicaldialogues  
LinkedIn:   / medical-dialogues  
Website: https://medicaldialogues.in/